That researchers and other stakeholders invest so much in evaluating treatments of AN likely reflects both the severity of the illness and the positive intent of those wishing to eradicate it. Failing to recruit sufficient numbers casts doubt over most conclusions, can influence later meta-analyses (e.g. Peters et al., 2006) , and, ultimately, does not do justice to those who volunteer to participate in these studies. If sufficient investment is given (alongside appropriate structural change; see Vankov et al., 2014; Higginson and Munafò, 2016) , rewards in terms of treatment outcomes should begin to emerge more clearly.
